At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 154 target
Drug / intervention
Eszopiclone +1 moredrug
Likely dose
Eszopiclone 3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Effect of Eszoplicone on Initial Continuous Positive Airway Pressure (CPAP) Compliance
In Brief
A Phase 4 clinical trial evaluating Eszopiclone and Placebo control for Obstructive Sleep Apnea. Completed, enrolled 154 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the efficacy of Eszopiclone in improving short and intermediate-term compliance with continuous positive airway pressure (CPAP) in patients newly diagnosed with obstructive sleep apnea (OSA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Sleep Apnea
CountriesUnited States
CollaboratorsSumitomo Pharma America, Inc.
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedFeb 2008
Primary CompletionJun 2008
Study CompletionFeb 2009
TodayJul 2026
First PostedFeb 11, 2008
Enrollment StartJan 1, 2008
Primary CompletionJun 1, 2008
Study CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.4 years ago
Interventions
Eszopiclonedrug
Eszopiclone 3mg orally at bedtime for 14 nights
Placebo controldrug
Matching placebo